Relief of pain associated with spasticity in adult patients after treatment with onabotulinumtoxinA : Post hoc observational results from the ASPIRE study
PM&R · 2025
DOI: 10.1002/pmrj.70013 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift PM&R, 2025. Verfasst von Jörg Wissel und 5 weiteren Autor:innen. Beteiligte Einrichtung: Neurology and Psychosomatic at Wittenbergplatz, Berlin, Germany. Hauptthemen laut MEDLINE: Muscle Spasticity, Botulinum Toxins, Type A, Pain Management, Pain. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AbbVie Inc.
Abstract (Originalsprache)
Background
Pain is often observed in patients with spasticity, but little is known about the relationship between pain and spasticity and the effectiveness of treating pain with botulinum toxins in these patients.
Objective
To explore onabotulinumtoxinA (onabotA) use and pain relief in patients with spasticity with pain at baseline.
Design
Subanalysis of a 2‐year multicenter, prospective, observational study (ASPIRE [Adult Spasticity International Registry], NCT01930786).
Setting
Fifty‐four international clinical sites.
Participants
Adults with spasticity ( N = 494) and pain at baseline (Numeric Pain Rating Scale [NPRS]>0) across multiple etiologies and age groups.
Intervention
OnabotA administered at clinician's discretion. Main Outcomes OnabotA use, pain measured with the NPRS and Disability Assessment Scale (DAS), patient‐ and physician‐reported satisfaction, and safety.
Results
Of 730 patients who received ≥1 onabotA dose in ASPIRE, 494 (68%) had baseline pain (mean age, 54 years; stroke, 56%; naïve to onabotA, 38%; NPRS ≥5, 65%). Average onabotA dose per treatment session (Tx) ranged from 345 to 463 U. Pain reduction from baseline was observed across all Tx; mean NPRS decreased from 5.4 to 2.6 at Tx8, model estimated mean NPRS was significantly reduced after each Tx (Tx1–7, p ≤ .001; Tx8, p ≤ .005), and a high proportion achieved clinically meaningful pain reductions across Tx1–4 (mean NPRS decreased by ≥30% for 49%–59%, by ≥50% for 40%–49%, and by ≥70% for 24%–34% of patients). Relief of pain was supported by significant improvements from baseline on the DAS pain subscale across most Tx with most patients/physicians being satisfied with onabotA treatment. Overall, 15 patients (3%) reported 17 treatment‐related adverse events (TRAEs), and 2 patients (0.4%) reported 3 serious TRAEs.
Conclusion
In patients with spasticity experiencing pain, long‐term onabotA treatment demonstrated consistent clinically meaningful reductions in pain, reduced pain disability on DAS, and high patient and physician satisfaction with no new safety signals identified, regardless of prior onabotA treatment or age groups.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Neurology and Psychosomatic at Wittenbergplatz, Berlin, Germany.
- Brooks Rehabilitation, Jacksonville, Florida, USA.
- MS Biostatistics, LLC, Clermont, Florida, USA.
- AbbVie, Irvine, California, USA.
- AbbVie, Inc., Rome, Italy.
- Hospital del Mar, Barcelona, Spain.
ORCID-Profile: Jörg Wissel
Förderung
- AbbVie Inc
Zitieren
APA
Wissel, J., List, C., Schwartz, M., Nelson, M., Musacchio, T., & Duarte, E. (2025). Relief of pain associated with spasticity in adult patients after treatment with onabotulinumtoxinA : Post hoc observational results from the ASPIRE study. PM&R. https://doi.org/10.1002/pmrj.70013
Vancouver
Wissel J, List C, Schwartz M, Nelson M, Musacchio T, Duarte E. Relief of pain associated with spasticity in adult patients after treatment with onabotulinumtoxinA : Post hoc observational results from the ASPIRE study. PM&R. 2025. doi:10.1002/pmrj.70013
BibTeX
@article{Wissel2025,
author = {Wissel, Jörg and List, Cassandra and Schwartz, Marc and Nelson, Mariana and Musacchio, Tiziana and Duarte, Esther},
title = {Relief of pain associated with spasticity in adult patients after treatment with onabotulinumtoxinA : Post hoc observational results from the ASPIRE study},
journal = {PM&R},
year = {2025},
doi = {10.1002/pmrj.70013}
}
EUVIMED